Skip to main content
Funded Studies

Ole Isacson, MD, PhD

Professor of Neurology and Neuroscience at Harvard Medical School

Director of the Neuroregeneration Research Institute at McLean Hospital

Location: Boston, MA United States

Ole Isacson, MD, PhD, is a professor of neurology and neuroscience at Harvard Medical School and founding director of the Neuroregeneration Research Institute (Neuroregeneration Laboratories) at McLean Hospital in Massachusetts. He is also principal faculty of the Harvard Stem Cell Institute. Dr. Isacson received his medical bachelor degree and doctorate in medicine (as a PhD degree and training in medical neurobiology) from the University of Lund in Sweden. His post-doctoral fellowship and training were at Cambridge University, UK. Upon completion of his fellowship, he was recruited as an assistant professor to start his own laboratory and program at Harvard Medical School, Massachusetts General Hospital and McLean Hospital. Dr. Isacson was editor-in-chief of Molecular and Cellular Neuroscience, a scientific journal, and is a member of several editorial boards. Dr. Isacson was selected to serve as a member of the Food and Drug Administration's Cellular, Tissue and Gene Therapies Advisory Committee from 2014 to 2017. In 2014, he was elected as a fellow of the American Association for the Advancement of Science (AAAS) for his research in Parkinson's disease (PD). He has published over 350 scientific articles and has received several awards for his work. Dr. Isacson's research aims to provide novel medicines, technology and biological insights beyond those currently available for PD.  

Associated Grants

  • Hexosaminidase as a Therapeutic Target for Parkinson's Disease


  • Autologous Long-Term Cell Restorative Therapy for Parkinson's Disease


  • The Role of LRRK2 in Neuronal Calcium Maintenance


  • Long-term Cell Restorative Treatment for Parkinson’s Disease


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.